Navigation Links
HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Date:11/9/2007

measured by the SELENA SLEDAI SLE Flare Index.

  • Sustained response to LymphoStat-B therapy was independent of the type of autoantibody at baseline.

A separate poster presentation reported that LymphoStat-B also promoted progressive normalization of autoantibody, immunoglobulin and complement levels over 2.5 years of therapy in SLE patients (Stohl et al), including:

  • Stable reductions in immunoglobulins, with no increase in infections or infectious events over time.

  • Normalization of IgG in patients with elevated IgG at baseline; from 45% to 57% of patients with hypergammaglobulinemia at baseline normalized at Weeks 52-128.

  • An increase in C3 and C4 complement among patients with low complement at baseline.

  • Reversion of autoantibody levels from positive to negative (anti-dsDNA, anti-RNP, anti-Smith).


'/>"/>

Contact: Jerry Parrot
Jerry_Parrott@hgsi.com
301-315-2777
Edelman Public Relations
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. Positive results for airway bypass
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Nanomedicine: Ending 'hit and miss' design 2Nanomedicine: Ending 'hit and miss' design 3From fruit fly wings to heart failure -- why Not(ch)? 2Physical education teaching staff play key role in making you like sport 2Magid Abou Gharbia Ph D FRSC Joins LAXAI as Scientific Advisor 13725 1Magid Abou Gharbia Ph D FRSC Joins LAXAI as Scientific Advisor 13725 2Magid Abou Gharbia Ph D FRSC Joins LAXAI as Scientific Advisor 13725 3U S Childhood Vaccine Rates Good But Could Be Better 3A CDC 55563 1U S Childhood Vaccine Rates Good But Could Be Better 3A CDC 55563 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 1ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 2ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 3ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 4ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 5ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 6ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 7ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 8ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 9ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 10ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 11ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 13ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 14ThromboGenics NV Announces Business Update and Half Year Results 2009 13723 15